Pfizer says data support quit-smoking drug’s safety

WASHINGTON (Reuters) - Data on Pfizer Inc’s smoking cessation drug Chantix continue to back the product’s safety, the company said on Wednesday after a watchdog group called for stronger warnings about risks.

Based on all data including clinical trials, “we stand by the efficacy and safety profile of Chantix when used as directed, an important treatment option to help patients stop smoking,” Pfizer spokeswoman Kristen Neese said in a statement.

The nonprofit Institute for Safe Medication Practices released an analysis earlier Wednesday that found more than 1,000 health problems, including 50 deaths, reported to U.S. regulators in the first quarter of 2008.

(Reporting by Lisa Richwine; Editing by Maureen Bavdek)


Related Posts:

By Ransdell Pierson NEW YORK (Reuters) - Pfizer Inc said on Friday it plans to pay $894 million to settle lawsuits alleging that its withdrawn Bextra painkiller and widely used Celebrex arthritis drug harmed U.S. patients and defrauded consumers. Pfizer said the money would be paid out under three separate tentative settlements — including one that resolves

Full Post: Pfizer to settle Bextra, Celebrex lawsuits

BRUSSELS (Reuters) - The European Commission confirmed on Thursday it had raided the French premises of a business association and an enterprise both active on the biomedical analysis market, on suspicion of cartel activity. The raids were carried out on Wednesday by Commission inspectors accompanied by officials at the French competition authority, it said. The parties

Full Post: EU exec raids suspected French biomedical cartel

BEIJING (Reuters) - China, fighting a spreading tainted milk scandal, needs a more coherent food-safety system, with unified laws, one overarching watchdog and faster sharing of information, the United Nations said on Wednesday. China has been swept by a series of food- and product-safety scandals involving goods as diverse as toys, tires, toothpaste, pet food, fish,

Full Post: China needs more coherent food-safety system: U.N.

NEW YORK (Reuters) - New data do not signal any heart risks with Takeda Pharmaceutical Co Ltd’s experimental drug to treat acid build-up in patients with gout, a top U.S. Food and Drug Administration official said in a document released on Thursday. Takeda is seeking U.S. approval to sell its drug febuxostat for chronic gout patients

Full Post: No heart risk seen with Takeda gout drug: FDA

WASHINGTON (Reuters) - The U.S. Food and Drug Administration, hampered by increasing globalization and a rise in complex products, may not be able to adequately protect the public’s health, the watchdog arm of Congress said in new findings released on Thursday. “As a result, the American consumer may not be adequately protected from unsafe and ineffective

Full Post: Report cites FDA’s weaknesses over drugs, devices

Site Navigation

Most Read